SYMBIOTEC PHARMALAB IPO
SYMBIOTEC PHARMALAB is a MAINBOARD IPO with a current status of LISTED. The price band is 938 - 988 . The issue opens on 24 AUG and closes on 27 AUG. The listing date is 01 SEP.
Price Band
938 - 988
Unofficial GMP
₹270
Lot Size
15 shares
Minimum Investment
₹14,070
SYMBIOTEC PHARMALAB IPO GMP
The latest available GMP is ₹270. Grey Market Premium is unofficial, may change frequently and does not guarantee the listing price, listing gains or investment returns.
Estimated Listing Price
₹1258.00
Estimated Gain
+27.3%
SYMBIOTEC PHARMALAB IPO GMP History
390
24 AUG
285
27 AUG
270
28 AUG
SYMBIOTEC PHARMALAB IPO Details
- IPO Type
- MAINBOARD
- Status
- LISTED
- Price Band
- 938 - 988
- Issue Size
- 1,757 CR
- Issue Type
- Book Build Issue Issue Size ₹1757.00 Cr
- Fresh Issue
- ₹150.00 Cr
- Offer for Sale
- ₹1607.00 Cr
- Face Value
- 2
- Lot Size
- 15
- Minimum Investment
- 14,070
- Exchange
- BSE, NSE
- Registrar
- MUFG Intime India Pvt.Ltd.
- Lead Managers
- JM Financial Ltd.
SYMBIOTEC PHARMALAB IPO Dates
- Open Date
- 24 AUG
- Close Date
- 27 AUG
- Allotment Date
- 28 AUG
- Refund Date
- 28 AUG
- Demat Credit Date
- 31 AUG
- Listing Date
- 01 SEP
SYMBIOTEC PHARMALAB IPO Subscription
- QIB
- 172.03x
- NII / HNI
- 73.61
- Retail
- 12.86x
- Employee
- 15.31x
- Total
- 71.20x
SYMBIOTEC PHARMALAB IPO Financials
Revenue
FY2026
₹869.15 Cr
+15.65% vs FY2025
PAT
FY2026
₹109.90 Cr
+13.56% vs FY2025
Total Assets
FY2026
₹1,780.79 Cr
+12.73% vs FY2025
| Particulars | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Revenue | 716.25 | 751.55 | 869.15 |
| Net Profit | 100.05 | 96.78 | 109.90 |
| Total Assets | 1,294.78 | 1,579.65 | 1,780.79 |
SYMBIOTEC PHARMALAB IPO Market Lot
| Category | Lots | Shares | Investment |
|---|---|---|---|
| Retail Minimum | 1 | 15 | ₹14,820 |
| Retail Maximum | 13 | 195 | ₹1,92,660 |
| Small HNI | 14 | 210 | 2,07,480 |
| Big HNI | 68 | 1,020 | ₹10,07,760 |
SYMBIOTEC PHARMALAB Company Overview
Symbiotec Pharmalab Limited is a research-driven pharmaceutical company specialising in Active Pharmaceutical Ingredients (APIs), particularly steroid and hormone APIs, and related pharmaceutical products. Established in 2002, the company has built capabilities across research, development and manufacturing for regulated and other international pharmaceutical markets.
SYMBIOTEC PHARMALAB Business Model
Manufacturing APIs and pharmaceutical intermediates Research & development Custom manufacturing Supplying pharmaceutical companies Domestic sales Exporting to international markets Developing specialised high-entry-barrier products The specialised nature of steroid APIs requires technical expertise, regulatory compliance and manufacturing capabilities, which create meaningful entry barriers.
SYMBIOTEC PHARMALAB Objects of the Issue
Fresh proceeds are intended toward company requirements including debt reduction and general corporate/business purposes, while the ~₹1,607 crore OFS proceeds will go to selling shareholders rather than Symbiotec. IPOWEB Important Point 🔴 Fresh Issue: ₹150 Cr 🟠 OFS: ~₹1,607 Cr Therefore, approximately 91%+ of the ₹1,757 crore IPO is OFS. This is an important factor to display prominently on IPOWEB.in.
SYMBIOTEC PHARMALAB Strengths
• Specialised position in steroid and hormone APIs, which require significant technical manufacturing capabilities. • Revenue increased to ₹869.15 crore in FY26. • FY26 PAT increased 13.54% to ₹109.90 crore. • Healthy EBITDA margin of approximately 26.59%. • PAT margin of approximately 12.60% is healthy for the business. • Borrowings declined from ₹540.92 crore in FY25 to ₹387.91 crore in FY26. • Established research and manufacturing capabilities. • Operates in pharmaceutical products with significant regulatory and technical barriers to entry. • Strong institutional interest is visible from the ₹526.20 crore anchor book.
SYMBIOTEC PHARMALAB Risks
• The IPO is heavily OFS-driven — approximately ₹1,607 crore of the ₹1,757 crore issue does not provide fresh capital to the company. • Borrowings remain significant at ₹387.91 crore as of FY26 despite falling from FY25 levels. • PAT declined from ₹100.06 crore in FY24 to ₹96.79 crore in FY25 before recovering to ₹109.90 crore in FY26. • ROE of 11.19% and RoNW of 9.48% are moderate compared with some listed pharmaceutical peers. • Pharmaceutical/API manufacturing is subject to stringent regulatory and quality-compliance requirements. • Any regulatory observations, manufacturing disruptions or quality-control failures can affect operations and customer relationships. • Foreign-market exposure can create currency, regulatory and geopolitical risks. • At roughly 52x FY26 earnings, absolute valuation is not cheap even though it is below several disclosed peers.
SYMBIOTEC PHARMALAB Frequently Asked Questions
What is the SYMBIOTEC PHARMALAB IPO price band?
The SYMBIOTEC PHARMALAB IPO price band is 938 - 988 .
What is the latest SYMBIOTEC PHARMALAB IPO GMP?
The latest available SYMBIOTEC PHARMALAB IPO GMP in the IPOWEB database is ₹270. GMP is unofficial and does not guarantee a listing gain.
When does the SYMBIOTEC PHARMALAB IPO open and close?
The SYMBIOTEC PHARMALAB IPO opens on 24 AUG and closes on 27 AUG.
When is the SYMBIOTEC PHARMALAB IPO allotment date?
The SYMBIOTEC PHARMALAB IPO allotment date is 28 AUG.
When is the SYMBIOTEC PHARMALAB IPO listing date?
The SYMBIOTEC PHARMALAB IPO listing date is 01 SEP.
What is the SYMBIOTEC PHARMALAB IPO subscription?
The latest total subscription available for the SYMBIOTEC PHARMALAB IPO is 71.20x.